Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 3
2009 10
2010 8
2011 9
2012 5
2013 6
2014 4
2015 5
2016 15
2017 12
2018 12
2019 5
2020 4
2021 3
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Results by year

Filters applied: . Clear all
Page 1
AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication.
Monjé N, Dragomir MP, Sinn BV, Hoffmann I, Makhmut A, Simon T, Kunze CA, Ihlow J, Schmitt WD, Pohl J, Piwonski I, Marchenko S, Keunecke C, Calina TG, Tiso F, Kulbe H, Kreuzinger C, Cacsire Castillo-Tong D, Sehouli J, Braicu EI, Denkert C, Darb-Esfahani S, Kübler K, Capper D, Coscia F, Morkel M, Horst D, Sers C, Taube ET. Monjé N, et al. Among authors: darb esfahani s. Br J Cancer. 2024 May;130(8):1249-1260. doi: 10.1038/s41416-023-02550-1. Epub 2024 Feb 9. Br J Cancer. 2024. PMID: 38361045 Free PMC article.
LRP1B-a prognostic marker in tubo-ovarian high-grade serous carcinoma.
Kolb S, Hoffmann I, Monjé N, Dragomir MP, Jank P, Bischoff P, Keunecke C, Pohl J, Kunze CA, Marchenko S, Schmitt WD, Kulbe H, Sers C, Sehouli J, Braicu EI, Denkert C, Darb-Esfahani S, Horst D, Sinn BV, Taube ET. Kolb S, et al. Among authors: darb esfahani s. Hum Pathol. 2023 Nov;141:158-168. doi: 10.1016/j.humpath.2023.09.001. Epub 2023 Sep 22. Hum Pathol. 2023. PMID: 37742945 Free article.
Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer.
Hoffmann I, Dragomir MP, Monjé N, Keunecke C, Kunze CA, Schallenberg S, Marchenko S, Schmitt WD, Kulbe H, Sehouli J, Braicu IE, Jank P, Denkert C, Darb-Esfahani S, Horst D, Sinn BV, Sers C, Bischoff P, Taube ET. Hoffmann I, et al. Among authors: darb esfahani s. Neoplasia. 2023 Oct;44:100934. doi: 10.1016/j.neo.2023.100934. Epub 2023 Sep 11. Neoplasia. 2023. PMID: 37703626 Free PMC article.
Correction to "Integration of Metabolomics and Expression of Glycerol-3-phosphate Acyltransferase (GPAM) in Breast Cancer─Link to Patient Survival, Hormone Receptor Status, and Metabolic Profiling".
Brockmöller SF, Bucher E, Müller BM, Budczies J, Hilvo M, Griffin JL, Orešič M, Kallioniemi O, Iljin K, Loibl S, Darb-Esfahani S, Sinn BV, Klauschen F, Prinzler J, Bangemann N, Ismaeel F, Fiehn O, Dietel M, Denkert C. Brockmöller SF, et al. Among authors: darb esfahani s. J Proteome Res. 2022 Jul 1;21(7):1787. doi: 10.1021/acs.jproteome.2c00181. Epub 2022 Jun 1. J Proteome Res. 2022. PMID: 35642679 No abstract available.
Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging.
Kassuhn W, Klein O, Darb-Esfahani S, Lammert H, Handzik S, Taube ET, Schmitt WD, Keunecke C, Horst D, Dreher F, George J, Bowtell DD, Dorigo O, Hummel M, Sehouli J, Blüthgen N, Kulbe H, Braicu EI. Kassuhn W, et al. Among authors: darb esfahani s. Cancers (Basel). 2021 Mar 25;13(7):1512. doi: 10.3390/cancers13071512. Cancers (Basel). 2021. PMID: 33806030 Free PMC article.
Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis.
Baum J, Braicu EI, Hunsicker O, Vergote I, Concin N, Van Nieuwenhuysen E, Feldheiser A, Achimas-Cadariu P, Darb-Esfahani S, Berger A, Fetica B, Mahner S, Papadia A, Wölber L, Gasparri ML, Vanderstichele A, Benedetti Panici P, Mueller MD, Ruscito I, Woopen H, Sehouli J. Baum J, et al. Among authors: darb esfahani s. Int J Gynecol Cancer. 2021 May;31(5):713-720. doi: 10.1136/ijgc-2020-002023. Epub 2021 Feb 9. Int J Gynecol Cancer. 2021. PMID: 33563640
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
Guo S, Loibl S, von Minckwitz G, Darb-Esfahani S, Lederer B, Denkert C. Guo S, et al. Among authors: darb esfahani s. Cancer Res Treat. 2020 Jul;52(3):689-696. doi: 10.4143/crt.2019.497. Epub 2020 Feb 4. Cancer Res Treat. 2020. PMID: 32019278 Free PMC article. Clinical Trial.
90 results